9 rows where ISSN contains "1048-891X"

View and edit SQL

Suggested facets: subject, references-count, is-referenced-by-count, author_number, created (date), title (array), subject (array), names (array), award_numbers (array), funder_names (array), funder_dois (array)

ISSN (array)

Link rowid ▼ title DOI URL created subject references-count is-referenced-by-count ISSN container-title abstract author_number orcids names award_numbers funder_names funder_dois
8 ["Increased Incidence of Severe Gastrointestinal Events With First-Line Paclitaxel, Carboplatin, and Vorinostat Chemotherapy for Advanced-Stage Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Cancer"] 10.1097/igc.0b013e31828566f1 http://dx.doi.org/10.1097/igc.0b013e31828566f1 2013-02-02T09:45:07Z [] 37 13 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:sec><jats:title>Objectives</jats:title><jats:p>We sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients were treated with 6 cycles of weekly paclitaxel (80 mg/m<jats:sup>2</jats:sup>), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board–approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m<jats:sup>2</jats:sup>) and vorinostat (400 mg) maintenance chemotherapy every 28 days.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Eighteen patients received a combined 90 cycles (median, 6 cycles; range, 1–6 cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and 2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1–12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study’s closure.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Because the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel res… 7 [] ["Alberto A. Mendivil", "John P. Micha", "John V. Brown", "Mark A. Rettenmaier", "Lisa N. Abaid", "Katrina L. Lopez", "Bram H. Goldstein"] [""] [""] [""]
10 ["Prognostic Impact of Parity in 493 Uterine Sarcoma Patients"] 10.1111/igc.0b013e3181aaa950 http://dx.doi.org/10.1111/igc.0b013e3181aaa950 2010-12-03T18:36:56Z ["Obstetrics and Gynaecology", "Oncology"] 28 11 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:sec><jats:title>Introduction:</jats:title><jats:p>Nulliparity has been found to negatively affect prognosis among endometrial cancer patients. Few previous studies have examined the prognostic impact of parity in patients with uterine sarcomas.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>In the present nationwide, register-based study in Norway, we explore whether parity influences survival among 493 women diagnosed with malignant uterine sarcomas. Hazard ratios for total mortality were calculated in Cox proportional hazard regression analyses.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>The 5-year Kaplan-Meier survival rates for the 126 endometrial stromal sarcoma (ESS) patients, 249 leiomyosarcoma (LS) patients, and 118 carcinosarcoma (CS) patients were 74%, 68%, and 55%, respectively, but varied considerably by age at diagnosis and clinical stage. In the univariate analyses, nulliparous women had poorer prognosis than parous women among CS patients (<jats:italic>P</jats:italic> = 0.071, log-rank test) and ESS patients (<jats:italic>P</jats:italic> = 0.15). In analyses adjusted for clinical stage and age at diagnosis, nulliparity was associated with a worse outcome in ESS patients only (hazard ratio, 0.50; 95% confidence interval, 0.22-1.12; parous vs nulliparous women); a trend with increasing number of births was also observed, of borderline significance (<jats:italic>P</jats:italic> = 0.058). No independent prognostic impact of parity was found in LS or CS patients. However, a considerably higher proportion of nulliparous than parous CS patients was diagnosed with advanced-stage disease (<jats:italic>P</jats:italic> = 0.003).</jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p>Nulliparity seems to be associated with poorer prognosis in ESS patients; no independent prognostic impact of parity was seen among LS or CS patients. Further knowledge on underlying biological mechanisms may be valuable for improved treatment.</jats:p></jat… 4 [] ["Grethe Albrektsen", "Ivar Heuch", "Elisabeth Wik", "Helga B. Salvesen"] [""] [""] [""]
11 ["Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index"] 10.1097/igc.0000000000001097 http://dx.doi.org/10.1097/igc.0000000000001097 2017-08-01T21:01:48Z [] 28 10 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:sec><jats:title>Objective</jats:title><jats:p>The present study assessed the predictive value of age and Modified Frailty Index (mFI) on the management of primary epithelial ovarian cancer (EOC) patients aged 70 years or older (elderly).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A retrospective multicenter study selected elderly EOC patients treated between 2006 and 2014. Treatments were analyzed according to the following age group categories: (1) 70 to 75 years versus (2) older than 75 years, and mFI of less than 4 (low frailty) versus greater than or equal to 4 (high frailty).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Seventy-eight patients were identified (40 in age group 1 and 38 in age group 2). The mFI was greater than or equal to 4 in 23 women. Median age of low frailty and high frailty was not significantly different (75.6 vs 75.3). Comorbidities were equally distributed according to age, whereas diabetes, hypertension, obesity, and chronic renal failure were more frequent in the high-frailty group. Performance status was different only according to mFI. Twenty percent of age group 1 versus 55.3% of age group 2 underwent none or only explorative surgical approach (<jats:italic>P</jats:italic> = 0.003), whereas surgical approaches were similar in the 2 frailty groups. The rate of postoperative complications was higher in high-frailty patients compared with low-frailty patients (23.5% vs 4.3%; <jats:italic>P</jats:italic> = 0.03). Chemotherapy was administered to all the patients, a monotherapy regimen to 50% of them. No differences in toxicity were registered, except more hospital recovery in the high-frailty cohort. Median survival time was in favor of younger patients (98 versus 30 months) and less-frailty patients (56 vs 27 months).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Elderly EOC patients can receive an adequate treatment, but patients who are older than 75 years can be undertreated, if not adequately selec… 8 [] ["Annamaria Ferrero", "Luca Fuso", "Elisa Tripodi", "Roberta Tana", "Alberto Daniele", "Valentina Zanfagnin", "Stefania Perotto", "Angiolo Gadducci"] [""] [""] [""]
12 ["Exploring the potential chemopreventative effect of aspirin and rofecoxib on hereditary nonpolyposis colorectal cancer\u2013like endometrial cancer cells in vitro through mechanisms involving apoptosis, the cell cycle, and mismatch repair gene expression"] 10.1111/j.1525-1438.2007.00867.x http://dx.doi.org/10.1111/j.1525-1438.2007.00867.x 2007-02-21T17:45:30Z [] 34 10 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:p>Women in hereditary nonpolyposis colorectal cancer (HNPCC) families have up to a 71% lifetime risk for developing endometrial cancer (EC). This compares to the female lifetime risk for colorectal cancer (CRC) in HNPCC of 60%. The basis of HNPCC is an inherited mutation in a mismatch repair gene (MMR). Aspirin and COX2 inhibitors seem to have a chemoprotective effect on CRC in the general population and are the subject of prospective clinical studies in patients at high risk for CRC including HNPCC. There is no evidence that these agents have any protective effect against EC in the general population. This study investigated the effect of aspirin and a COX2 inhibitor (rofecoxib) on an HNPCC EC cell line model (Ishikawa) by assessing the effect on proliferation, apoptosis, the cell cycle, and MMR gene expression. Aspirin inhibits EC cell proliferation by inducing apoptosis and changes in the cell cycle. This effect is not mediated by changes in MMR gene (hMSH2) expression as assessed by quantitative reverse transcription–polymerase chain reaction. Rofecoxib inhibits EC cell proliferation; this did not appear to be mediated by induction of apoptosis, by alterations of the cell cycle, or by changes in MMR gene expression</jats:p> 5 [] ["N. J. Wood", "N. A. Quinton", "S. Burdall", "E. Sheridan", "S. R. Duffy"] [""] [""] [""]
29 ["Ovarian fibrosarcoma with long-term survival: A case report"] 10.1136/ijgc-00009577-200107000-00016 http://dx.doi.org/10.1136/ijgc-00009577-200107000-00016 2019-03-05T12:15:23Z ["Obstetrics and Gynaecology", "Oncology"] 0 3 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:sec><jats:title>Abstract.</jats:title><jats:p>Huang Y-C, Hsu K-F, Chou C-Y, Dai Y-C, Tzeng C-C. Ovarian fibrosarcoma with long-term survival.</jats:p><jats:p>Primary ovarian fibrosarcoma is an exceedingly rare malignant ovarian stromal tumor which has a poor prognosis. We report here a 46-year-old woman who suffered from irregular vaginal bleeding for 2 months. She received hysterectomy and salpingo-oophorectomy due to a provisional diagnosis of uterine and ovarian tumors. At surgery, an 8-cm ovarian solid multilobular tumor was found. Frozen section examination revealed an ovarian fibrosarcoma. She then underwent staging procedures including intraperitoneal washing, cytology, and pelvic and para-aortic lymph node sampling. Final pathologic examination revealed that the tumor exhibited densely packed spindle cells in storiform configuration with obvious increased mitotic activity. In addition, the flow cytometric study showed marked elevated percentage of tumor cells in the S phase (13.1%). After surgery, the patient received six courses of combination chemotherapy with epirubicin, ifosfamide, and dacarbazine (DTIC). The patient stood the treatment well and is free from disease 6 years later.</jats:p></jats:sec> 5 [] ["Y.-C. Huang", "K.-F. Hsu", "C.-Y. Chou", "Y.-C. Dai", "C.-C. Tzeng"] [""] [""] [""]
38 ["A case of protrusion of an intraperitoneal chemotherapy catheter through rectum"] 10.1136/ijgc-00009577-200501000-00026 http://dx.doi.org/10.1136/ijgc-00009577-200501000-00026 2019-03-06T16:30:38Z ["Obstetrics and Gynaecology", "Oncology"] 0 1 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:p>Bowel penetration of an intraperitoneal catheter occurred in a patient who had received a course of uncomplicated intraperitoneal chemotherapy for a persistent ovarian carcinoma. One month after the termination of chemotherapy, she presented with protrusion of a catheter through anus. At operation, the catheter was removed, the rectum was repaired primarily, and a cytoreductive surgery was performed.</jats:p> 5 [] ["Y. Bilsel", "E. Balik", "D. Bugra", "S. Yamaner", "A. Akyuz"] [""] [""] [""]
60 ["Successful use of anti-retroviral therapy in combination with cytotoxic chemotherapy for persistent molar pregnancy: A case report"] 10.1136/ijgc-00009577-200303000-00026 http://dx.doi.org/10.1136/ijgc-00009577-200303000-00026 2019-03-06T09:50:37Z ["Obstetrics and Gynaecology", "Oncology"] 0 0 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:p>Due to the HIV pandemic, the chances of finding gynecological malignancies in HIV-infected women are increased. This poses management and ethical dilemmas as the treatment for such malignancies are likely to further decrease their immunity. Gestational trophoblastic disease occurs predominantly among young women and has excellent response to chemotherapy. However, such therapy is not possible if their immunity (CD<jats:sub>4</jats:sub> counts) is markedly depressed. The patient described presented with persistent molar pregnancy and had low CD<jats:sub>4</jats:sub> count. She was given antiretroviral therapy and once the CD<jats:sub>4</jats:sub> count had risen to acceptable levels cytotoxic chemotherapy was administered. She received a total of 13 cycles of chemotherapy with no significant untoward effects. After a 6-month follow-up period the patient was well with a negative serum βHCG level and CD<jats:sub>4</jats:sub> count above 200. We conclude that HIV-infected women with gestational trophoblastic disease may be safely treated with cytotoxic chemotherapy provided anti-retroviral therapy is concurrently administered to boost immunity.</jats:p> 2 [] ["M. Moodley", "J. Moodley"] [""] [""] [""]
62 ["The Selection of Time Interval Between Surgery and Adjuvant Therapy in Early Stage Cervical Cancer"] 10.1097/igc.0000000000001307 http://dx.doi.org/10.1097/igc.0000000000001307 2018-08-02T22:02:59Z ["Obstetrics and Gynaecology", "Oncology"] 21 0 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:sec><jats:title>Objectives</jats:title><jats:p>The optimal interval between surgery and adjuvant treatment has not yet been found in cervical cancer. And whether patients with different FIGO stage should choose different interval is unknown. The purpose of this study was to evaluate whether interval has a different effect on oncologic outcome for patients with different tumor stages.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We performed a retrospective study of 226 cervical cancer patients who were treated by surgery and adjuvant therapy from May 2005 to August 2015. All patients were divided into 2 groups according to the interval of 5 weeks. Overall survival (OS) and disease-free survival (DFS) were compared between patients with interval shorter and longer than 5 weeks in the whole group and subgroups. Recurrence patterns were also analyzed. Multivariate analysis was performed to explore clinical factors significantly associated with DFS, local recurrence-free survival and distant metastasis-free survival for patients with stage IB2–IIA.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>For patients with stage IA2–IB1, the 5-year OS and DFS were similar between groups of short and long interval with also the comparable results of local and distant failure. For patients with IB2–IIA, both the OS and DFS in the short-interval group were higher than that in the long-interval group. Besides, the rates of local recurrence were found higher in the group of long interval compared with short interval. Multivariable analysis indicated that time interval was an independent predictor of DFS and local recurrence-free survival for patients with stage IB2–IIA.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In cervical cancer patients, time interval between surgery and adjuvant therapy may have different effects on the prognosis in different FIGO stages.</jats:p></jats:sec> 6 [] ["Kai-Yun You", "Xin-Hui Zhou", "Yan-Hui Jiang", "Zhuo-Fei Bi", "Yi-Min Liu", "Xing-Sheng Qiu"] [""] [""] [""]
71 ["Phase III randomized pilot study comparing interferon \u03b1- 2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix"] 10.1136/ijgc-00009577-200303000-00011 http://dx.doi.org/10.1136/ijgc-00009577-200303000-00011 2019-03-06T14:50:37Z ["Obstetrics and Gynaecology", "Oncology"] 0 0 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:p>This randomized pilot study was designed to determine whether the addition of interferon α-2b to standard radiation therapy offered an advantage in loco-regional control and survival over radiation therapy alone in a homogeneous group of patients with stage IIIB carcinoma of the cervix. Thirty-six patients were treated with a combination of interferon α-2b plus radiation therapy, and 38 patients were treated with radiation therapy alone. Patients with evidence of ureteral obstruction were excluded from the study. Evaluation of loco-regional response was determined by pelvic examination, cervical cytology, biopsies and CT scans when indicated. Survival time was measured from initiation of treatment to date of death or last follow-up. Patient characteristics were comparable between both study arms. The objective complete response rate was 67% in the combined therapy group and 55% in the radiation alone group (<jats:italic>P</jats:italic> = 0.454). With a median follow-up of 17 months for all patients and 31 months for live patients, 50% of the combined group survived vs. 39.5% of the radiation alone group (<jats:italic>P</jats:italic> = 0.424). We conclude that the addition of interferon α-2b to standard radiation therapy did not significantly improve loco-regional response or survival, although such a trend was noted. We encourage the design of a larger randomized study with sufficient power to detect meaningful differences to prove whether the tendency observed in the present investigation holds any promise to improve the outcome of these patients.</jats:p> 14 [] ["R. Yazigi", "G. Aliste", "R. Torres", "A. M. Ciudad", "M. Cuevas", "J. Garrido", "S. Prado", "A. Sol\u00e1", "R. Castillo", "B. Cerda", "M. A. Cumsille", "M. Gonz\u00e1lez", "C. Navarro", "J. M. Reyes"] [""] [""] [""]

Advanced export

JSON shape: default, array, newline-delimited

CSV options:

CREATE TABLE [article] (
   [title] TEXT,
   [DOI] TEXT,
   [URL] TEXT,
   [created] TEXT,
   [subject] TEXT,
   [references-count] TEXT,
   [is-referenced-by-count] TEXT,
   [container-title] TEXT,
   [abstract] TEXT,
   [author_number] TEXT,
   [orcids] TEXT,
   [names] TEXT,
   [award_numbers] TEXT,
   [funder_names] TEXT,
   [funder_dois] TEXT